MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Revolution Medicines, Inc. - Common Stock (NQ:RVMD)

187.53 -4.64 (-2.41%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 31, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Revolution Medicines, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
The FDA Just Granted Its Speediest Review Ever. Disc Medicine, Others Fly. ↗
The Commissioner's National Priority Review vouchers aims to speed up the review process to just one to two months. 
Via Investor's Business Daily
News headline image
FDA Unveils First Experimental Drugs Under Fast-Track Voucher Plan To Cut Drug Review Times ↗
The FDA launched a new voucher program to fast-track reviews, naming nine experimental drugs for cancer, diabetes, addiction, and other conditions. 
Via Benzinga
News headline image
'No Need To Sell' Martin Marietta Materials, Cramer Says: 'It's Just A Great Long-Term Hold' ↗
Wells Fargo's Timna Tanners initiated coverage on Martin Marietta Materials with an Equal-Weight rating and announced a price target of $620. 
Via Benzinga
News headline image
Revolution Medicines, Disc Medicine, Regeneron Stocks Jump After-Hours As FDA Fast-Tracks 9 Drugs Under New Review Program ↗
The FDA’s new National Priority Voucher pilot helps with faster drug reviews, cutting timelines from nearly a year to weeks. 
Via Stocktwits
News headline image
Earnings Scheduled For August 6, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 7, 2025 ↗
 
Via Benzinga
News headline image
A Glimpse of Revolution Medicines's Earnings Potential ↗
 
Via Benzinga
News headline image
Earnings Scheduled For February 26, 2025 ↗
 
Via Benzinga
News headline image
Analysts Raise Price Targets Following Strong Data From Revolution Medicines' Pancreatic Cancer Drug ↗
Revolution Medicines reports positive results from daraxonrasib trials in metastatic pancreatic cancer, with strong response rates and consistent safety data. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Aon To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Thursday ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
Top 3 Health Care Stocks That Could Blast Off In December ↗
 
Via Benzinga
News headline image
This Parker-Hannifin Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday ↗
 
Via Benzinga
News headline image
Revolution Medicines Inc (NASDAQ:RVMD) Reports Q2 2025 Earnings Miss, Shares Drop 4.5% After-Hours ↗
Revolution Medicines (RVMD) missed Q2 2025 revenue and EPS estimates, reporting $0 revenue and a -$1.31 loss. Shares dropped 4.5% amid investor concerns, despite progress in Phase 3 trials for... 
Via Chartmill
Topics Earnings
News headline image
This GitLab Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday ↗
 
Via Benzinga
News headline image
Revolution Medicines and Summit Therapeutics Enter Into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors With Ivonescimab in RAS Mutant Tumors
From Summit Therapeutics Inc.
Via Business Wire
News headline image
Revolution Medicines To Advance Lead Cancer Drug With $2 Billion In Funds ↗
Revolution Medicines signs a $2 billion funding deal with Royalty Pharma to support its RAS(ON) pipeline, including daraxonrasib development and launch. 
Via Benzinga
News headline image
Revolution Medicines To Get Up To $2B For Development Of Cancer Drug From Royalty Pharma ↗
Royalty Pharma will provide up to $1.25 billion to Revolution Medicines in exchange for a synthetic royalty on annual worldwide net sales of Daraxonrasib for a term of 15 years and a senior secured... 
Via Stocktwits
News headline image
Groupon Posts Upbeat Earnings, Joins Axon Enterprise, Warner Bros. Discovery, MercadoLibre And Other Big Stocks Moving Higher On Thursday ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
Why Is Cancer Drug Developer Revolution Medicines Stock Trading Higher On Monday? ↗
Revolution Medicines shared Phase 1 data showing zoldonrasib's acceptable safety profile in KRAS G12D mutant solid tumors at AACR 2025. 
Via Benzinga
News headline image
Dow Dips 150 Points; ISM Manufacturing PMI Tops Estimates ↗
 
Via Benzinga
Topics Stocks
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Stellantis, PG&E And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Top 3 Health Care Stocks That Should Keep You Up At Night This Quarter ↗
 
Via Benzinga
News headline image
Microsoft To Rally Around 6%? Here Are 10 Top Analyst Forecasts For Tuesday ↗
 
Via Benzinga
News headline image
Why Helen of Troy Shares Are Trading Lower By Around 30%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
 
Via Benzinga
News headline image
Nvidia, Micron, Arlo Technologies And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
The 7 Most Undervalued Under-$50 Stocks to Buy in June 2024 ↗
Undervalued stocks under $50 hold significant appeal, but as every investor knows, value is in the eye of the beholder 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story